SNCA and Parkinsonism: Lower CBE doses over a sustained period of time more closely resemble GBA1 mutation carriers, with approximately 50% residual GCase activity, and creates a more Parkinson-like phenotype, with increased oligomeric α-synuclein levels, brain-wide neurodegeneration, and microglial activation [101].